About
AccuLine was founded with the vision to save the lives of millions of people worldwide by preventing the next heart attack. AccuLine is developing CORA – an accurate, non-invasive, swift, and cost-effective examination for early detection of CAD, designed to replace the inaccurate, time-consuming, and labor-intensive stress test examinations.
Through a brief 4-minute evaluation of three vital signs - the heart's electrical activity, oxygen saturation levels, and respiratory phase, CORA automatically generates results, ensuring a seamless and efficient process. CORA has the potential to save the lives of millions of patients worldwide, while simultaneously decreasing health care-related costs.
AccuLine has received grants from Google and the Israeli Innovation Authority, and among its shareholders are Mayo Clinic, eHealth Ventures and Maccabi Healthcare Services.
Funding history · 2 rounds · $6.3M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is AccuLine's primary focus?
- AccuLine is developing CORA, a non-invasive examination for the early detection of Coronary Artery Disease (CAD) to prevent heart attacks, aiming to replace traditional stress tests.
- When was AccuLine founded?
- AccuLine was founded in February 2022.
- How many employees does AccuLine currently have?
- AccuLine currently has 12 employees.
- What is the total amount of funding AccuLine has raised?
- AccuLine has raised a total of $6,255,000 USD.
- Which notable organizations are shareholders in AccuLine?
- Mayo Clinic, eHealth Ventures, and Maccabi Healthcare Services are among AccuLine's shareholders.
- Has AccuLine received any grants?
- AccuLine has received grants from Google and the Israeli Innovation Authority, including two grants totaling $750,000 in May 2024, and an additional grant of $930,000.
- What was a significant partnership announced by AccuLine in September 2023?
- In September 2023, AccuLine announced a Know-How License Agreement with Mayo Clinic to advance the early detection of heart attacks.
- What is the current product stage of CORA?
- CORA is currently in the clinical trial stage.
- Which Israeli program did AccuLine participate in during November 2022?
- In November 2022, AccuLine was one of six startups participating in Assuta's 'RISE with US' program, which focuses on international market expansion.